Worldwide Selects Medidata’s Payments Cloud for CRO Experience
NEW YORK – July 12, 2017 – Global provider of cloud-based technology and data analytics for clinical research, Medidata, announced that its Medidata Payments Cloud has been selected by Worldwide Clinical Trials (Worldwide) to streamline payments on behalf of their clinical trial sponsors.
Medidata Payments Cloud is a global site payment technology for the industry that’s driven by EDC. It focuses on studies across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. Worldwide will leverage Medidata Payments Cloud to trigger, calculate, and disburse payments directly into an investigative site’s bank account, to benefit the CRO experience for sponsors and sites.
“Worldwide’s success as a CRO is down to our ability to partner successfully with our trial sponsors and sites – going above and beyond in the delivery, operation and support of all of our services,” said Anthony Doyle, Chief Financial Officer, Worldwide. “Medidata Payments Cloud stood out as a truly end-to-end solution, driven by EDC, and for the opportunity it provides us to reimburse sites as quickly and accurately as possible – important as we invest in processes and technology that help Worldwide continue to stand out as a top-ranked performer for service and customer loyalty.”
“Timeliness and accuracy in payments are critical to the success of contract research organizations, and achieving both can be incredibly challenging,” said April Mulroney, Managing Director of Payments at Medidata. “We’re proud that Worldwide has selected Medidata Cloud Payments, which will help them create an industry-leading site payment operation, ensuring sites are easily paid on time, and reporting to sponsors is accurate and timely.”
Medidata Contacts
Investor: Anthony D’Amico, +1 732-767-4331, adamico@mdsol.com
Media: Erik Snider, Medidata Solutions, +1 646-362-2997, esnider@mdsol.com
Worldwide Contacts
Media: Sherri Stuart, Worldwide Clinical Trials, +1 610-563-8768, sherri.stuart@worldwide.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
